Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

National Institute of Allergy and Infectious Diseases (NIAID)

Status and phase

Active, not recruiting

Early Phase 1

Conditions

CGD

Chronic Granulomatous Disease

Treatments

Biological: JSP191

Study type

Interventional

Funder types

NIH

Identifiers

NCT05600907

000609-I

10000609

Details and patient eligibility

About

Background:

Chronic granulomatous disease (CGD) is a rare immune disorder that can cause serious infections throughout the body. The only cure for CGD is a stem cell transplant. Transplants from a sibling are best, but many people must get transplants from unrelated donors. However, these transplants can cause serious complications in people with CGD.

Objective:

To see if a study drug (JSP191) can help improve the success rates of stem cell transplants for people with CGD from an unrelated donor.

Eligibility:

People aged 4 to 65 years with CGD who require a transplant.

Design:

Participants will be screened. Part of the screening will help to identify the best match to a transplant donor. Participants will have a physical exam, including dental and eye exams. They will have blood and urine tests. They will have tests of their breathing and heart function. A bone marrow sample will be taken. They will have their stem cells collected.

Participants will have a catheter inserted into a vein in their chest. It will remain in place for the entire period of transplant and recovery.

Participants will be in the hospital 40 to 50 days for the transplant. This will include a conditioning phase, to prepare their body for the procedure, as well as the transplant and recovery phases. As part of the conditioning phase, participants will receive JSP191 through a vein for 1 hour.

After discharge, participants will have follow-up visits 2 times a week for 100 days. Additional follow-up visits will continue for 5 years....

Full description

Study Description:

This is a pilot study for individuals with chronic granulomatous disease (CGD) using an unmanipulated matched unrelated donor (MUD) graft. The conditioning regimen will use alemtuzumab (Campath-1H, Genzyme Corporation) and total body irradiation (TBI) combined with the investigational new drug JSP191.

Participants will receive a high-dose donor graft infusion followed by post-transplant cyclophosphamide (Cytoxan, Baxter International, Inc). This study will determine whether replacing busulfan with the new investigational drug, JSP191, within the alemtuzumab/TBI-based conditioning regimen yields engraftment in patients with CGD.

Objectives:

Primary Objective:

- To measure the engraftment rates using JSP191 in conjunction with a high cell-dose graft.

Secondary Objectives:

To assess overall survival.
To evaluate the safety and efficacy of JSP191 in a TBI- and alemtuzumab-based regimen for transplantation of unmanipulated unrelated donor grafts in patients with CGD.
Assessment of graft versus host disease (GvHD).
Evaluate the long-term engraftment of those receiving JSP191.
To assess the level and kinetics of immune reconstitution.
To evaluate the pharmacokinetic (PK) properties of JSP191 in patients with CGD.

Exploratory Objectives:

To assess the impact of inflammatory cytokines on engraftment, inflammatory reactions, and graft rejection.
To further elucidate the factors involved in the development of GvHD and graft rejection/failure.

Endpoints:

Primary Endpoint:

- Reduced incidence of graft failure or rejection (as defined by >= 20% engraftment by oxidase-positive neutrophils in >= 85% of participants by Day 100, 1 year, and 2 years after transplant). Myeloid chimerism and/or oxidase positivity of >= 20% will be considered engrafted.

Secondary Endpoints:

Overall survival.
Safety will be evaluated by recording of adverse events (AEs) related to JSP191 rather than to GvHD or engraftment. An increase in incidence of AEs or development of AEs not typically seen in patients receiving a busulfan-based regimen will be attributed to the use of JSP191.
Assessment of rates of GvHD.
Rates of grade 3 and 4 acute GvHD (aGvHD) of < 20% (see Appendix B on grading).
Development and incidence of aGvHD and chronic GvHD

(cGvHD) with a comparison to historical controls and incidence on parallel protocols using busulfan.

Engraftment at >2 years and up to 5 years post-transplant.
Reconstitution kinetics using absolute neutrophil and absolute

lymphocyte recovery kinetics will be compared as well as impact on immunoglobulin (Ig) levels.

- PK will be measured and compared to historical data supplied by Jasper Therapeutics, Inc. and from other patient populations on other studies at the NIH.

Exploratory Endpoints:

Evaluation of inflammatory markers as risk factors for engraftment syndrome and/or graft failure.
Obtain samples for cytokine profiles at various timepoints post-transplant to assess the impact on inflammation profiles by JSP191 in the setting of the conditioning regimen.

Enrollment

7 patients

Sex

All

Ages

4 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

INCLUSION CRITERIA:
Has confirmed CGD.
Has sufficient complications from underlying disease to warrant undergoing transplantation (either a history of or ongoing inflammation/CGD-related autoimmunity OR a CGD-related infection while on prophylaxis) OR has a Quartile 1 or 2 residual oxidase production level.
Aged 4 years to 65 years.
Has an unrelated matched donor available (but no matched related donor available).
Must be able to stay within 1 hours travel of the NIH for the first 3 months after transplantation and have a family member or other designated companion to stay with during the post-transplant period.
Must provide a durable power of attorney for health care decisions to an appropriate adult relative or guardian in accordance with form NIH 200 NIH Durable Power of Attorney for Health Care Decision Making.
If of childbearing potential, must agree to consistently use contraception from 1 month prior to baseline, throughout study participation, and for 1 year after receiving transplanted cells. Acceptable forms of contraception are:
- Contraceptive pills or patch, Norplant, Depo-Provera, or other FDA-approved contraceptive method.
- Male partner has previously undergone a vasectomy.
If able to impregnate a partner, must agree to consistently use contraception from the time of enrollment through 3 months post-transplant. Acceptable forms of contraception are:
- Male condom with spermicide.

EXCLUSION CRITERIA:

Eastern Cooperative Oncology Group (ECOG) or equivalent performance status >= 3 (see Supportive Care guidelines, available at https://training.seer.cancer.gov/followup/procedures/dataset/ecog.html).
Left ventricular ejection fraction < 40%.
Transaminases > 5x upper limit of normal based on the individual s clinical situation and at the discretion of the investigator.
CRP > 100 mg/dL within 6 weeks of the transplant.
Psychiatric disorder or mental deficiency severe enough as to make compliance with the HSCT unlikely, and/or to make regulatorily and legally effective informed consent impossible.
Major anticipated illness or organ failure incompatible with survival from allogeneic HSCT.
Pregnant or breastfeeding.
HIV positive.
Uncontrolled seizure disorder.
Any condition or circumstance that the PI feels would create difficulty in maintaining compliance with the requirements of this protocol.
Individuals who are not willing to submit their information as part of the alemtuzumab (Campath) Distribution Program application or participants whom the Distribution Program committee has determined are not qualified to receive alemtuzumab.

NOTE: Alemtuzumab (IV formulation) is no longer distributed commercially. In order to receive product, the physician must contact the program for the patient. If the patient is not willing to consent to submit their information (demographics, contact information, and rationale for use) to the program such that we can obtain the drug, then we cannot proceed with conditioning; therefore, the individual will not be eligible for this protocol.